scientific programme
26
Monday, 23 June 2014
PL-01
PLENARY LECTURE
09:00–09:45
Plenary Hall A
Track: Basic
Topic: Depression (A)
The Arvid Carlsson Lecture: The ups and
downs of amphetamines: A diversity of ac-
tions on cellular signaling pathways
Susan G. Amara, USA
Learning Objectives:
Delegates who attended
this presentation would gain a greater insight
into the action of amphetamines and how these
action contribute to a person gaining an ad-
diciton to those drugs.
S-01
SYMPOSIUM
10:00–12:00
Ballroom A
Track: Translational
Topic: Depression (A)
Remodeling the neurocircuitry of depres-
sion: Ketamine and glutamate
Chair:
Anthony Grace, USA
Co-Chair: Rupert Lanzenberger, Austria
S-01-001
Current treatments of depression: Impact of
monoamine and glutamate
Pierre Blier, Canada
K. El Iskandarani, C. A. Oosterhof, M. El Mansari
S-01-002
Results of brain imaging of Ketamine using
fMRI and PET
Rupert Lanzenberger, Austria
S-01-003
Prefrontal-amygdala attenuation of dopa-
mine neuron activity in animal models of
depression: Reversal by Ketamine
Anthony Grace, USA
P. Belujon, C.-H. Chang
S-01-004
Too little or too much? The place of gluta-
mate in depression
Maurizio Popoli, Italy
Learning Objectives:
This symposium will
update delegates on developments in under-
standing how ketamine is functioning as an
antidepressant drug and the possibility that
this will lead to new drug treatments.
S-02
SYMPOSIUM
10:00–12:00
Ballroom B
Track: Basic
Topic: Schizophrenia (A)
Neuron-glia interaction in schizophrenia:
Focus on D-serine
Chair:
Mikhail Pletnikov, USA
Co-Chair: Toru Nishikawa, Japan
S-02-001
Neuron-glia regulation of D-serine signaling:
Implication in schizophrenia
Toru Nishikawa, Japan
S-02-002
D-Serine localization: Fact or artifact
Joseph Coyle, USA
D. Balu, M. Puhl, M. Benneyworth, S. Takagi
S-02-003
Role of glia-neuron crosstalk and the neuro-
nal Asc-1 transporter in D-serine dynamics:
Implications for schizophrenia
Herman Wolosker, Israel
S-02-004
DISC1-serine racemase interaction in as-
trocytes: At the intersection of two major
pathways of schizophrenia
Mikhail Pletnikov, USA
Learning Objectives:
D-serine is a poten-
tial new lead compound for the treatment of
schizophrenia. This symposium will provide
an update on progress being made in under-
standing the mechanisms by which this drug
can have therapeutic effects.
S-03
SYMPOSIUM
10:00–12:00
Ballroom C
Track: Basic
Topic: Bipolar disorder (A)
Developing novel drug classes for bipolar
disorder
Chair:
Tadafumi Kato, Japan
Co-Chair: Husseini Manji, USA
S-03-001
Development of mood stabilizers based on
mitochondrial dysfunction hypothesis of bi-
polar disorder
Tadafumi Kato, Japan
